Skip to main content
Article thumbnail
Location of Repository

The amyloid beta ion channel hypothesis of Alzheimer’s disease

By Najeeb A Shirwany, Daniel Payette, Jun Xie and Qing Guo


Alzheimer’s disease (AD) is a leading cause of chronic dementia in the US. Its incidence is increasing with an attendant increase in associated health care costs. Since its first description in a patient by Dr. Alois Alzheimer over a century ago, a large body of biomedical literature has established a detailed clinical and molecular profile of this disorder. Amyloid β peptide (Aβ; a 39–42 amino acid molecule) is the major component of senile plaques, the lesions that are one of the pathologic hallmarks of AD (Wong et al 1985). Although many aspects of the biology of amyloid β have been investigated, several fundamental questions about how this peptide causes AD neuropathology remain unanswered. The key question is: How is Aβ toxic to cerebral neurons? Because plaques are extra-neuronal deposits, it is difficult to imagine a structural basis for their toxicity. As an interesting contrast the other pathognomonic feature of AD, neurofibrillary tangles, are intra-axonal structural anomalies that are composed of the hyperphosphorylated microtubule associated (MAP) protein, tau. This review will assess the current thinking that relates to a recent hypothesis of Aβ toxicity. In 1992, Hardy and Higgins reported findings that suggested a new and intriguing possibility. These authors found that Aβ peptides disrupt Ca2+ homeostasis in neurons and increase intracellular Ca2+ [Ca2+]i. This was corroborated by Mattson and his colleagues who demonstrated that Aβ exposure to human cortical neurons raised [Ca2+]i (Mattson, Cheng et al 1992); (Hardy and Higgins 1992). Finally, Nelson Arispe’s group at the NIH specifically investigated the possibility that Aβ peptides might function like Ca2+ ion channels (Arispe et al 1993). This and several subsequent studies have laid the foundation for a novel idea: “Aβ peptides are, in part, toxic to neurons because they form aberrant ion channels in neuronal membranes and thereby disrupt neuronal homeostasis”. In this review we shall critically examine this theory in light of classic and contemporary literature

Topics: Reviews
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). A modifi ed beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide – the fi rst step of a fatal cascade.
  2. (2004). Acetylcholinesterase-Abeta complexes are more toxic than Abeta fi brils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss.
  3. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fi brils.
  4. (2005). Advancing age alters rapid and spontaneous refi lling of caffeine-sensitive calcium stores in sympathetic superior cervical ganglion cells.
  5. (2007). Age-dependent changes in Ca2+ homeostasis in peripheral neurones: implications for changes in function.
  6. (1996). alpha-calcium-calmodulin-dependent kinase II is associated with paired helical fi laments of Alzheimer’s disease.
  7. (1999). Alzheimer amyloid abeta1-42 channels: effects of solvent, pH, and Congo Red.
  8. (1997). Alzheimer’s A beta(1–42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells.
  9. (1997). Alzheimer’s disease amyloid betaprotein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons.
  10. (2001). Alzheimer’s disease-like alterations in peripheral cells from presenilin-1 transgenic mice.
  11. (2001). Alzheimer’s disease: genes, proteins, and therapy.
  12. (1984). Alzheimer’s disease: initial report of the purifi cation and characterization of a novel cerebrovascular amyloid protein.
  13. (1992). Alzheimer’s disease: the amyloid cascade hypothesis.
  14. (2007). Alzheimer’s Facts and Figures.” [online] Accessed on
  15. (1994). Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res,
  16. (1996). Amyloid beta peptide of Alzheimer’s disease downregulates Bcl-2 and upregulates bax expression in human neurons.
  17. (1999). Amyloid beta protein (1-40) forms calciumpermeable, Zn2+-sensitive channel in reconstituted lipid vesicles.
  18. (1995). Amyloid beta protein (A beta) in Alzheimer’s disease brain. Biochemical and immunocytochemical analysis with antibodies specifi c for forms ending at A beta 40 or A beta 42(43).
  19. (2001). Amyloid beta protein 1–40 and 1–42 levels in matched cerebrospinal fl uid and plasma from patients with Alzheimer disease.
  20. (1997). Amyloid beta protein 42(43) in cerebrospinal fl uid of patients with Alzheimer’s disease.
  21. (1989). Amyloid beta protein enhances the survival of hippocampal neurons in vitro.
  22. (2001). Amyloid beta protein forms ion channels: implications for Alzheimer’s disease pathophysiology.
  23. (1998). Amyloid beta protein increases Ca2+ currents in rat cerebellar granule neurones.
  24. (1998). Amyloid beta protein-(1–42) forms calciumpermeable, Zn2+-sensitive channel.
  25. (1992). Amyloid beta-peptide is produced by cultured cells during normal metabolism.
  26. (2006). Amyloid ion channels: a porous argument or a thin excuse?”
  27. (1996). Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation.
  28. (1991). An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P.
  29. (2006). Anti-Abeta42- and anti-Abeta40-specifi c mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
  30. (2000). Antioxidants prevent amyloid peptideinduced apoptosis and alteration of calcium homeostasis in cultured cortical neurons.
  31. (2006). Apoptosis and necrosis: a review for surgeons.
  32. (2003). APP processing and synaptic function.
  33. (2004). Architecture of the Alzheimer’s A beta P ion channel pore.
  34. (1999). Association of microglia with amyloid plaques in brains of APP23 transgenic mice.
  35. (1996). Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer’s disease: an immunohistochemical study using end-specifi c A beta monoclonal antibodies.
  36. (1998). Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord,
  37. (1994). Beta-amyloid neurotoxicity requires fi bril formation and is inhibited by congo red.
  38. (1992). beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity.
  39. (1995). beta-Amyloid precursor protein-defi cient mice show reactive gliosis and decreased locomotor activity.
  40. (1990). Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage.
  41. (2000). Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease.
  42. (2000). Blockage of amyloid beta peptide-induced cytosolic free calcium by fullerenol-1, carboxylate C60 in PC12 cells.
  43. (2007). Calcium and neurodegeneration.
  44. (1993). Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF.
  45. (1996). Calcium-induced calcium release in neurones.
  46. (1997). Calpains and calpastatin in SH-SY5Y neuroblastoma cells during retinoic acid-induced differentiation and neurite outgrowth: comparison with the human brain calpain system.
  47. (2001). Clearing the brain’s amyloid cobwebs.
  48. (1994). Cloned glutamate receptors. Annu Rev Neurosci,
  49. (1997). Contribution of somal Lewy bodies to neuronal death. Brain Res,
  50. (2003). Cu2+-induced modifi cation of the kinetics of A beta(1-42) channels.
  51. (2001). Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria.
  52. (1998). Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture.
  53. (2005). Determinants of postsynaptic Ca2+ signaling in Purkinje neurons.
  54. Disease and Treatment 2007:3(5) 610 Shirwany et al Arispe
  55. (1997). Distinct sites of intracellular production for Alzheimer’s disease A beta40/42 amyloid peptides. Nat Med, 3(9):1016–20.Neuropsychiatric Disease and Treatment 2007:3(5) 611 Amyloid beta channel and Alzheimer’s
  56. (2006). Early and late cytotoxic effects of external application of the Alzheimer’s Abeta result from the initial formation and function of Abeta ion channels.
  57. (1999). Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides.
  58. (2002). Erratic expression of DNA polymerases by beta-amyloid causes neuronal death.
  59. (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway.
  60. (2007). Expansion of the calcium hypothesis of brain aging and Alzheimer’s disease: minding the store. Aging Cell,
  61. (2000). Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channelmediated cellular toxicity.
  62. (2000). From form to function: calcium compartmentalization in dendritic spines.
  63. (2000). Functional triads consisting of ryanodine receptors, Ca(2+) channels, and Ca(2+)-activated K(+) channels in bullfrog sympathetic neurons. Plastic modulation of action potential.
  64. (1997). Generation of Alzheimer beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation.
  65. (1990). Genetics and biology of the Alzheimer amyloid precursor. Prog Brain Res,
  66. (1997). Giga-ohm seals on intracellular membranes: a technique for studying intracellular ion channels in intact cells.
  67. (2003). H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK.
  68. (2004). Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease.
  69. (2000). Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.
  70. (1998). Hypersensitivity to seizures in beta-amyloid precursor protein defi cient mice.
  71. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfl ugers
  72. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death.
  73. (1999). Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice.
  74. (2004). Induction of pro-apoptotic calsenilin/DREAM/ KChIP3 in Alzheimer’s disease and cultured neurons after amyloid-beta exposure.
  75. (1995). Inositol 1, 4, 5-trisphosphate receptormediated Ca2+ signaling in the brain.
  76. (1998). Integrative Aspects of Calcium Signalling.
  77. (2004). Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer’s disease. Histol Histopathol,
  78. (1997). Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis.
  79. (1999). Intracellular APP processing and A beta production in Alzheimer disease.
  80. (1997). Intracellular ATP levels determine cell death fate by apoptosis or necrosis.
  81. (1997). Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42.
  82. (2000). Intraneuronal Abeta42 accumulation in human brain.
  83. (2002). Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology.
  84. (2002). Intraneuronal APP/A beta traffi cking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.
  85. (2006). Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with fi ve familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation.
  86. (1990). Ion channels in the nuclear envelope.
  87. (1997). Ionic effects of the Alzheimer’s disease beta-amyloid precursor protein and its metabolic fragments.
  88. (1986). Isolation and partial characterization of neurofi brillary tangles and amyloid plaque core in Alzheimer’s disease: immunohistological studies.
  89. (1986). Isolation of low-molecular-weight proteins from amyloid plaque fi bers in Alzheimer’s disease.
  90. (2005). Mar. Molecule of the month.
  91. (1999). Memantine in severe dementia: results of the 9M-Best Study (Benefi t and effi cacy in severely demented patients during treatment with memantine).
  92. (1998). Modifi cation of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity.
  93. (2002). Modulation of Ca2+ channel currents in primary cultures of rat cortical neurones by amyloid beta protein (1–40) is dependent on solubility status.
  94. (1994). Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci,
  95. (2004). Molecular mechanisms of glutamatedependent neurodegeneration in ischemia and traumatic brain injury.
  96. (1998). Mouse cortical neurones lacking APP show normal neurite outgrowth and survival responses in vitro.
  97. (1985). Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related.
  98. (1993). Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state.
  99. (2006). Neuropathologic changes in Alzheimer’s disease: potential targets for treatment.
  100. (2003). Neuropathologic changes in Alzheimer’s disease.
  101. (2002). Neurotoxic effects of thiofl avin S-positive amyloid deposits in transgenic mice and Alzheimer’s disease.
  102. (1990). Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.
  103. (2005). NMDA receptor activation inhibits alphasecretase and promotes neuronal amyloid-beta production.
  104. (1970). Observations on the brains of demented old people.
  105. (1968). Observations on the brains of nondemented old people.
  106. (2004). Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.
  107. (2000). Parameters of calcium homeostasis in normal neuronal ageing.
  108. (1992). Patch clamp techniques to study ion channels from organelles. Methods Enzymol,
  109. (2006). Physiological roles for amyloid beta peptides.
  110. (2002). Presenilins are not required for A beta 42 production in the early secretory pathway.
  111. (2005). Presynaptic Ca2+ dynamics, Ca2+ buffers and synaptic effi cacy.
  112. (2003). Protofi brils, pores, fi brils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci,
  113. (1993). Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.
  114. (2002). Senile plaque composition and posttranslational modifi cation of amyloid-beta peptide and associated proteins.
  115. (2004). Small assemblies of unmodifi ed amyloid beta-protein are the proximate neurotoxin in Alzheimer’s disease.
  116. (2006). Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure.
  117. (1994). Solution structure of residues 1–28 of the amyloid beta-peptide.
  118. (2004). Stereoselective Inhibition of Amyloid Beta Peptide Secretion by LY450139, A Novel Functional Gamma Secretase Inhibitor. Neurobiol Aging, 25(Suppl 2):S571.
  119. (2004). Structure and function of amyloid in Alzheimer’s disease.
  120. (1998). Structure and function of neuronal Ca2+ channels and their role in neurotransmitter release.
  121. (1998). Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer’s amyloid-beta toxicity and oxidative stress.
  122. (1992). Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments.
  123. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.
  124. (1993). The C-terminus of the beta protein is critical in amyloidogenesis.
  125. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease.
  126. (2005). The development of anti-amyloid therapy for Alzheimer’s disease : from secretase modulators to polymerisation inhibitors.
  127. (1986). The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities.
  128. (1997). The pathogenesis of senile plaques.
  129. (1994). The pharmacology of intracellular Ca(2+)-release channels.
  130. (2003). The production of amyloid beta peptide is a critical requirement for the viability of central neurons.
  131. (1998). The role of A Beta 42 in Alzheimer’s disease.
  132. (2000). The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer’s disease.
  133. (2000). The voltage sensor in voltage-dependent ion channels.
  134. (1994). Theoretical models of the ion channel structure of amyloid beta-protein.
  135. (2004). Transgenic animal models of Alzheimer’s disease and related disorders: histopathology, behavior and therapy.
  136. (2003). Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.
  137. (1998). Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester.
  138. (2001). Ultrastructure evidence of necrotic neural cell death in familial Alzheimer’s disease brains bearing presenilin-1 E280A mutation.
  139. (1994). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specifi c A beta monoclonals: evidence that an initially deposited species is A beta 42(43).
  140. (2006). Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology.
  141. (1996). Zn2+ interaction with Alzheimer amyloid beta protein calcium channels.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.